Drugs / Silymarin
Trials 35
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07058090 | Jul → Dec 2025 overdue | drug-induced liver injury, tuberculosis | Liaquat National Hospital & Medical College | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT01752153 | Jun → Sep 2012 | immunodeficiency disease | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01018615 | Nov 2009 → Apr 2013 | chronic hepatitis C virus infection, disorder of defective peroxisome oxidative status | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1 | NCT00389376 | Nov 2006 → Jan 2008 | NAFLD1, hepatitis C virus infection | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 1 | NCT00065741 | Sep 2003 → Mar 2006 | — | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 1 | NCT00011635 | Feb → Jun 2001 | HIV infectious disease | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00246363 | Jan 2005 → Dec 2007 | HIV infectious disease, chronic hepatitis C virus infection | Henry Sacks | Completed | No outcome recorded |
| Phase 212 trials · 1 met primary · 3 missed | ||||||
| Phase 2 | NCT07572552 | May 2026 → Apr 2027 expected | infectious disease with sepsis | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06213857 | Feb → May 2025 overdue | ulcerative colitis | Tanta University | Recruiting | No outcome recorded |
| Phase 2 | NCT06425705 | Feb 2022 → Jul 2023 | type 2 diabetes mellitus | Lahore General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03982849 | Jul → Dec 2019 | hyperpigmentation of the skin | Islamabad Medical and Dental College | Completed | No outcome recorded |
| Phase 2 | NCT02473913 | Mar 2015 → Jun 2018 | trichotillomania | University of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT02006498 | Jun 2012 → Dec 2015 | NAFLD1 | University of Malaya | Completed | Missed primary |
| Phase 2 | NCT01003236 | Oct 2010 → Oct 2011 | diabetic kidney disease | Shiraz University of Medical Sciences | Completed | Met primary |
| Phase 2 | NCT01001845 | Jun 2009 → Mar 2010 | end stage renal failure | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00680342 | Apr 2008 → Jan 2011 | chronic hepatitis C virus infection | National Center for Complementary and Integrative Health (NCCIH) | Completed | Missed primary |
| Phase 2 | NCT00680407 | Apr 2008 → Nov 2012 | metabolic dysfunction-associated steatohepatitis | Madaus Inc | Completed | Missed primary |
| Phase 2 | NCT01292161 | Mar → Sep 2006 | hepatitis C virus infection | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00030030 | Jul 2000 → Jun 2002 | chronic hepatitis C virus infection | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05144217 | Jun 2021 → Dec 2024 | drug-induced liver injury | Prof. Dr. Frank Behrens | Completed | No outcome recorded |
| Phase 2/3 | NCT01049178 | Sep 2010 | allergic asthma | Vanderbilt University | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/3 | NCT00999349 | Mar → Dec 2009 | beta-thalassemia major, disorder of iron metabolism and transport | Isfahan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT06114719 | Jan 2023 → Sep 2024 | atrial fibrillation | University of Novi Sad | Completed | No outcome recorded |
| Phase 3 | NCT04394208 | Aug 2020 → Jan 2021 | COVID-19, viral pneumonia | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT06801886 | Jan 2020 → Dec 2025 overdue | acute transplant rejection, diabetes mellitus, hypertensive nephropathy | University Hospital, Martin | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT01258686 | Nov 2010 → Nov 2012 | chronic hepatitis C virus infection | Bukwang Pharmaceutical | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT05666765 | Jan → Nov 2023 | acne | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT05099601 | May → Dec 2022 | hyperpigmentation of the skin | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT05849558 | Feb 2022 → Dec 2023 | liver disorder | MinaPharm Pharmaceuticals | Unknown | No outcome recorded |
| Phase 4 | NCT04490967 | Apr → Dec 2021 | acne | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT02973295 | Sep 2019 → Dec 2020 | NAFLD1 | University Hospital Rijeka | Withdrawn | No outcome recorded |
| Phase 4 | NCT03130634 | Apr 2016 → Jun 2019 | colorectal cancer | Kaohsiung Medical University Chung-Ho Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00412763 | Jul 2003 → Oct 2005 | hepatitis | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07293767 | Nov 2024 → Jan 2026 overdue | fibromyalgia | Ain Shams University | Recruiting | No outcome recorded |
| — | NCT01436929 | Sep 2011 → Oct 2013 | tuberculosis | Seoul National University Hospital | Unknown | No outcome recorded |
| Comparator or background therapy19 trials | ||||||
| Phase 0 | NCT05523648 Background | Jan 2020 → Dec 2021 | NAFLD1, chronic hepatitis B virus infection | Sichuan Leshan Traditional Chinese Medicine Hospital | Completed | No outcome recorded |
| Phase 2 | NCT07001150 Comparator | May 2025 → May 2026 overdue | Parkinson disease | Tanta University | Recruiting | No outcome recorded |
| Phase 2 | NCT02337634 Comparator | Jan 2015 → Dec 2022 | pathological gambling | University of Chicago | Completed | No outcome recorded |
| Phase 2/3 | NCT05595109 Comparator | Oct 2022 → Apr 2023 | breast cancer, chemotherapy-induced toxicity, cognitive impairment with or without cerebellar ataxia, peripheral neuropathy | Tanta University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01829178 Comparator | Aug 2013 → Sep 2014 | cisplatin toxicity, gastroesophageal adenocarcinoma | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT07863648 Comparator | Oct 2026 → Aug 2027 expected | metabolic dysfunction-associated steatotic liver disease | Kafrelsheikh University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07833514 Background | Sep 2026 → Jun 2027 expected | NAFLD1, alcoholic liver disease, drug-induced liver injury | Hanoi Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05631041 Comparator | Dec 2022 → Nov 2024 | colorectal cancer | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT02878863 Background | Aug 2016 → Mar 2017 | autoimmune hepatitis | Xiaoli Fan | Withdrawn | No outcome recorded |
| Phase 3 | NCT01091324 Comparator | Jan → Jun 2010 | proteinuria | National Cheng-Kung University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06724952 Comparator | Dec 2024 → Mar 2025 overdue | rheumatoid arthritis | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04816682 Comparator | Mar → Jun 2021 | COVID-19, liver disorder | F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica | Completed | No outcome recorded |
| Phase 4 | NCT05042245 Comparator | Jul 2019 → Dec 2022 | NAFLD1 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| — | NCT06922669 Background | Jun 2025 → Mar 2027 expected | drug-induced liver injury | General Hospital of Shenyang Military Region | Recruiting | No outcome recorded |
| — | NCT06277635 Comparator | Feb 2024 → Apr 2025 | psoriasis, psoriatic arthritis | Phramongkutklao College of Medicine and Hospital | Unknown | No outcome recorded |
| — | NCT05626881 Comparator | May → Dec 2022 | hyperpigmentation of the skin | Sohag University | Unknown | No outcome recorded |
| — | NCT03659058 Comparator | Mar 2016 → Aug 2018 | fibrotic liver disease | Zagazig University | Completed | No outcome recorded |
| — | NCT03547895 Comparator | Jun 2015 → May 2016 | cirrhosis of liver | Zagazig University | Completed | No outcome recorded |
| — | NCT01800487 Comparator | Jan 2012 → Jun 2013 | tuberculosis | Ramathibodi Hospital | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 56 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Silymarin | “The control group was treated with silymarin glucosamine tablets (Jiangsu Zhongxing Pharmaceutical Co., Ltd.; National medicine permission number: H32026233; Production batch:...” NCT05523648 ↗53“Silymarin is a complex mixture of 6 major flavonolignans and other minor polyphenolic compounds derived from the milk thistle plant Silybum marianum; it has shown antioxidant,...” PMID 28419855 ↗ Apr 2017 “Silymarin (milk thistle), an extract obtained from Silybum marianum seeds containing a complex of flavonolignans with a potent intracellular antioxidant property.” NCT06213857 ↗ “Patients were randomly assigned to 2 equal groups to receive three 140-mg tablets of silymarin or 3 tablets of placebo daily for 3 months.” PMID 22770926 ↗ Jul 2012 “Silymarin or Milk Thistle may therefore offer promise for the treatment of individuals with trichotillomania.” NCT02473913 ↗ “Silymarin,a mixture of three isomeric flavonolignans, is isolated from milk thistle (Silybum marianum) seeds” NCT01001845 ↗ “In this clinical study silymarin will be administered in different dosages and compared to placebo” NCT05144217 ↗ “Silymarin (derived from milk thistle) has antioxidant properties.” PMID 38478366 ↗ Mar 2024 “Silymarin 420 mg in 3 divided dose plus standard chemotherapy” NCT01829178 ↗ “Silymarin was manufactured with concentration of 1.4%” NCT05626881 ↗ “Ursoplus® capsules (UDCA 250mg & Silymarin 140mg)” NCT05849558 ↗ |
| Known as | LEGALON | “Silymarin (LEGALON)” NCT07293767 ↗ |
| Known as | milk thistle | “vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion” NCT03547895 ↗4“Silymarin or Milk Thistle may therefore offer promise for the treatment of individuals with gambling disorder.” NCT02337634 ↗ “Silymarin or Milk Thistle may therefore offer promise for the treatment of individuals with trichotillomania.” NCT02473913 ↗ “Silymarin (milk thistle)” NCT00246363 ↗ “Silymarin (milk thistle)” NCT00011635 ↗ |
| Known as | Silymarin capsule | “Drug: Silymarin capsule” NCT05042245 ↗ |
| Known as | Silymarin capsules | “Silymarin capsules in the active comparator arm.” NCT05042245 ↗ |
| Action | Activate | “silymarin, an inducer of antioxidant enzymes” NCT01049178 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Silymarin (Milk thistle) is a commonly used dietary supplement in HIV-infected patients for treatment of hepatitis or as a hepato-protectant.” NCT00011635 ↗ |
| Route | Oral | “given concurrently via the oral route” NCT00065741 ↗ |
| Target | STAT3 | “As a direct inhibitor of STAT3-a master checkpoint regulator of inflammatory cytokine signaling and immune response” PMID 32517353 ↗ Jun 2020 |